Showing 1 - 4 results of 4 for search 'Allison L. Naleway', query time: 0.02s Refine Results
  1. 1
    Attitudes toward a future norovirus vaccine among members of an integrated healthcare delivery system in Portland, Oregon, 2016-2017

    Attitudes toward a future norovirus vaccine among members of an integrated healthcare delivery system in Portland, Oregon, 2016-2017 by Holly C. Groom, Mark Schmidt, Laura E. Calderwood, Sara A. Mirza, Claire Mattison, Suzanne Salas, Judy Donald, Allison L. Naleway

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study

    Methods to Adjust for Confounding in Test-Negative Design COVID-19 Effectiveness Studies: Simulation Study by Elizabeth AK Rowley, Patrick K Mitchell, Duck-Hye Yang, Ned Lewis, Brian E Dixon, Gabriela Vazquez-Benitez, William F Fadel, Inih J Essien, Allison L Naleway, Edward Stenehjem, Toan C Ong, Manjusha Gaglani, Karthik Natarajan, Peter Embi, Ryan E Wiegand, Ruth Link-Gelles, Mark W Tenforde, Bruce Fireman

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance.

    Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. by James Hollister, Cynthia Porter, Ryan Sprissler, Shawn C Beitel, James K Romine, Jennifer L Uhrlaub, Lauren Grant, Young M Yoo, Ashley Fowlkes, Amadea Britton, Lauren E W Olsho, Gabriella Newes-Adeyi, Sammantha Fuller, Pearl Q Zheng, Manjusha Gaglani, Spencer Rose, Kayan Dunnigan, Allison L Naleway, Lisa Gwynn, Alberto Caban-Martinez, Natasha Schaefer Solle, Harmony L Tyner, Andrew L Philips, Kurt T Hegmann, Sarang Yoon, Karen Lutrick, Jefferey L Burgess, Katherine D Ellingson

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysisResearch in context

    Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023–March 2024: a test-negative design analysisResearch in context by Amanda B. Payne, Steph Battan-Wraith, Elizabeth A.K. Rowley, Melissa S. Stockwell, Sara Y. Tartof, Kristin Dascomb, Stephanie A. Irving, Brian Dixon, Sarah W. Ball, Mark W. Tenforde, Gabriela Vazquez-Benitez, Ashley B. Stephens, Jungmi Han, Karthik Natarajan, S. Bianca Salas, Cassandra Bezi, Lina S. Sy, Bruno Lewin, Tamara Sheffield, Julie Arndorfer, Daniel Bride, Josh Van Otterloo, Allison L. Naleway, Padma D. Koppolu, Shaun Grannis, William Fadel, Colin Rogerson, Tom Duszynski, Sarah E. Reese, Patrick K. Mitchell, Sean Chickery, Heidi L. Moline, Morgan Najdowski, Allison Avrich Ciesla, Emily L. Reeves, Malini DeSilva, Katherine E. Fleming-Dutra, Ruth Link-Gelles

    Published 2025-09-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: